-
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational…
-
Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug, XY0206. The drug is intended for use in treating acute myeloid leukemia (AML) with FLT3-ITD mutation (FMS-like tyrosine kinase 3 internal…
-
Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received approval from the US FDA for a clinical trial of its novel depression therapy, KH607. This marks a significant milestone for the company as it advances its innovative treatment through the regulatory pipeline in the…
-
Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter
•
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the enrollment of the first patient in a prospective, multi-center, randomized controlled clinical study. The study is designed to assess the efficacy and safety of Blue Sail Medical’s rapamycin-coated balloon dilation catheter for arteriovenous fistula in…
-
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
•
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion cohort of the TranStar102 trial at the ESMO Congress 2023 in Madrid, Spain. The trial assessed osemitamab (TST001), a high affinity humanized anti-CLDN18.2 monoclonal antibody (mAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC), in combination with…
-
Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment
•
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its VUM02, a Category 1 therapeutic biologic product. This human umbilical cord-derived mesenchymal stem cell therapy is intended…
-
Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio
•
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings, a biotechnology firm co-owned by UK’s Roivant Sciences (NASDAQ: ROIV) and US-based Pfizer (NYSE: PFE). The acquisition will grant Roche rights to RVT-3101, a potential best-in-class and first-in-class anti-TL1A subcutaneous antibody, in the US and…
-
J&J MedTech Partners with CED Medical for Neurointerventional Solutions
•
Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd, has entered into a strategic partnership with CED Medical, a neuroscience device marker headquartered in Nantong, near Shanghai. The collaboration aims to expand market reach, promote technology, and foster innovation in the field of neurointerventional…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
